Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Table 1 Baseline characteristics of the patients treated with tolvaptan and controls
| Characteristic | TLV group (n = 60) | Controls (n = 60) | P |
| Age (yr) | 67.1 ± 11.2 | 69.5 ± 9.0 | 0.21 |
| Male | 46 (76.7%) | 46 (76.7%) | 1.00 |
| Bodyweight (kg) | 61 (54-69) | 64 (55-73) | 0.58 |
| HCV antibody positive | 36 (60.0%) | 35 (58.3%) | 1.00 |
| Child-Pugh class C | 27 (45.0%) | 24 (40.0%) | 0.71 |
| Refractory ascites | 56 (93.3%) | 60 (100%) | 0.12 |
| Hepatic hydrothorax | 32 (53.3%) | 29 (48.3%) | 0.72 |
| Liver neoplasms stage 3, 4a, or 4b | 26 (43.3%) | 25 (41.7%) | 1.00 |
| Serum albumin (g/dL) | 2.8 (2.5-3.1) | 2.8 (2.5-3.1) | 0.98 |
| Total bilirubin (mg/dL) | 2.7 (0.7-3.1) | 2.8 (1.1-3.6) | 0.81 |
| ALT (IU/L) | 42 (20-44) | 36 (20-53) | 0.27 |
| Serum creatinine (mg/dL) | 1.40 (0.90-1.61) | 1.45 (0.78-1.59) | 0.30 |
| eGFR (mL/min per 1.73 m2) | 43.1 (31.0-62.7) | 49.8 (33.5-67.8) | 0.95 |
| Serum sodium (mEq/L) | 133 (130-136) | 136 (132-139) | 0.02 |
| Platelet count (× 103/μL) | 114 (58-147) | 95 (69-139) | 0.80 |
| Prothrombin activity (%) | 58.7 (45.0-70.0) | 57.3 (42.3-70.2) | 0.71 |
- Citation: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1685